 | • レポートコード：MRC2303J0142 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、234ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社は、世界の抗肥満処方薬市場規模が2021年に5,342.71百万ドル、2022年には5,761.56百万ドルに到達し、今後CAGR 8.01％で成長して2027年までに8,486.13百万ドルまで拡大すると予測しています。当調査資料では、抗肥満処方薬の世界市場について調査・分析を行い、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、薬物分類別（ブプロピオン＆ナルトレキソン、リラグルチド、ロルカセリン、オルリスタット、フェンテルミン＆トピラマート）分析、年齢層別（成人、小児）分析、流通チャネル別（病院薬局、オンライン薬局、小売薬局）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの項目をまとめております。なお、当書に掲載されている企業情報には、7TM Pharma A/S、Akrimax Pharmaceuticals Inc、Alizyme PLC、Arena Pharmaceuticals, Inc、Arrowhead Pharmaceuticals、Bayer AG、Bristol-Myers Squibb Co、C.H. Boehringer Sohn AG & Ko. KG、Cadila Healthcare Limited、Currax Pharmaceuticals LLC、Eisai Co., Ltdなどが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の抗肥満処方薬市場規模：薬物分類別 - ブプロピオン＆ナルトレキソン - リラグルチドの市場規模 - ロルカセリンの市場規模 - オルリスタットの市場規模 - フェンテルミン＆トピラマートの市場規模 ・世界の抗肥満処方薬市場規模：年齢層別 - 成人における市場規模 - 小児における市場規模 ・世界の抗肥満処方薬市場規模：流通チャネル別 - 病院薬局チャネルの市場規模 - オンライン薬局チャネルの市場規模 - 小売薬局チャネルの市場規模 ・世界の抗肥満処方薬市場規模：地域別 - 南北アメリカの抗肥満処方薬市場規模 アメリカの抗肥満処方薬市場規模 カナダの抗肥満処方薬市場規模 ブラジルの抗肥満処方薬市場規模 ... - アジア太平洋の抗肥満処方薬市場規模 日本の抗肥満処方薬市場規模 中国の抗肥満処方薬市場規模 インドの抗肥満処方薬市場規模 韓国の抗肥満処方薬市場規模 台湾の抗肥満処方薬市場規模 ... - ヨーロッパ/中東/アフリカの抗肥満処方薬市場規模 イギリスの抗肥満処方薬市場規模 ドイツの抗肥満処方薬市場規模 フランスの抗肥満処方薬市場規模 ロシアの抗肥満処方薬市場規模 ... - その他地域の抗肥満処方薬市場規模 ・競争状況 ・企業情報 |
The Global Anti-obesity Prescription Drugs Market size was estimated at USD 5,342.71 million in 2021 and expected to reach USD 5,761.56 million in 2022, and is projected to grow at a CAGR 8.01% to reach USD 8,486.13 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Anti-obesity Prescription Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Drug Class, the market was studied across Bupropion and Naltrexone, Liraglutide, Lorcaserin, Orlistat, and Phentermine and Topiramate.
Based on Age Group, the market was studied across Adult and Pediatric.
Based on Distribution Channel, the market was studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Anti-obesity Prescription Drugs market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Anti-obesity Prescription Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Anti-obesity Prescription Drugs Market, including 7TM Pharma A/S, Akrimax Pharmaceuticals Inc, Alizyme PLC, Arena Pharmaceuticals, Inc, Arrowhead Pharmaceuticals, Bayer AG, Bristol-Myers Squibb Co, C.H. Boehringer Sohn AG & Ko. KG, Cadila Healthcare Limited, Currax Pharmaceuticals LLC, Eisai Co., Ltd, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Merck & Co., Norgine BV, Novo Nordisk A/s, Orexigen Therapeutics, Inc, Pfizer Inc,, Rhythm Pharmaceuticals, Inc., Shionogi USA Inc, Takeda Pharmaceutical Company Limited, Vivus Inc, and Zafgen Inc.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Anti-obesity Prescription Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Anti-obesity Prescription Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Anti-obesity Prescription Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Anti-obesity Prescription Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Anti-obesity Prescription Drugs Market?
6. What is the market share of the leading vendors in the Global Anti-obesity Prescription Drugs Market?
7. What modes and strategic moves are considered suitable for entering the Global Anti-obesity Prescription Drugs Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of obesity and related chronic diseases
5.1.1.2. Growing unhealthy and sedentary lifestyle
5.1.1.3. Advancement in medical research by drug-manufacturing companies, medical universities and institutes, and government agencies
5.1.2. Restraints
5.1.2.1. Side effect related to anti-obesity drugs
5.1.3. Opportunities
5.1.3.1. Introduction of novel anti-obesity drugs
5.1.4. Challenges
5.1.4.1. Availability of alternative treatment options
5.2. Cumulative Impact of COVID-19
6. Anti-obesity Prescription Drugs Market, by Drug Class
6.1. Introduction
6.2. Bupropion and Naltrexone
6.3. Liraglutide
6.4. Lorcaserin
6.5. Orlistat
6.6. Phentermine and Topiramate
7. Anti-obesity Prescription Drugs Market, by Age Group
7.1. Introduction
7.2. Adult
7.3. Pediatric
8. Anti-obesity Prescription Drugs Market, by Distribution Channel
8.1. Introduction
8.2. Hospital Pharmacy
8.3. Online Pharmacy
8.4. Retail Pharmacy
9. Americas Anti-obesity Prescription Drugs Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Anti-obesity Prescription Drugs Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Anti-obesity Prescription Drugs Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. 7TM Pharma A/S
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Akrimax Pharmaceuticals Inc
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Alizyme PLC
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Arena Pharmaceuticals, Inc
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Arrowhead Pharmaceuticals
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Bayer AG
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Bristol-Myers Squibb Co
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. C.H. Boehringer Sohn AG & Ko. KG
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Cadila Healthcare Limited
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Currax Pharmaceuticals LLC
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Eisai Co., Ltd
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. F. Hoffmann-La Roche AG
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. GlaxoSmithKline PLC
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Merck & Co.
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Norgine BV
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Novo Nordisk A/s
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. Orexigen Therapeutics, Inc
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Pfizer Inc,
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Rhythm Pharmaceuticals, Inc.
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. Shionogi USA Inc
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
13.21. Takeda Pharmaceutical Company Limited
13.21.1. Business Overview
13.21.2. Key Executives
13.21.3. Product & Services
13.22. Vivus Inc
13.22.1. Business Overview
13.22.2. Key Executives
13.22.3. Product & Services
13.23. Zafgen Inc
13.23.1. Business Overview
13.23.2. Key Executives
13.23.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing